Financing
Guardant Health·Cash Flow Statement·14 metrics
Breakdown
| Metric | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Net cash from financing activities | $5.9M | -$2.9M | -$2.9M | -$66.9M | — | — | $732M | -$21.6M |
| Taxes paid for net share settlement | $3.2M | $2.9M | $8M | $15.5M | $7.4M | $2.3M | $5.4M | $20.7M |
| Other, net | -$438K | -$31K | — | -$3K | -$41K | $2.9M | $765K | -$4.5M |
| Payment of Deferred Purchase Consideration | -$438K | -$31K | — | -$3K | -$41K | $2.9M | $765K | -$4.5M |
| Noncontrolling interest transactions and other | -$438K | -$31K | — | -$3K | -$41K | $2.9M | $765K | -$4.5M |
| Other financing activities | -$438K | -$31K | — | -$3K | -$41K | $2.9M | $765K | -$4.5M |
| Noncontrolling Interests Activity and Other | -$438K | -$31K | — | -$3K | -$41K | $2.9M | $765K | -$4.5M |
| Proceeds from issuance of common stock | -$213K | $0 | $0 | $768K | $1.6M | $3.7M | $327.3M | $3.7M |
| Payments Of Debt Issuance Costs | $0 | $0 | $0 | $12.1M | $151K | $0 | $12.3M | $102K |
| Payment of debt issuance costs | $0 | $0 | $0 | $12.1M | $151K | $0 | $12.3M | $102K |
| Proceeds from convertible debt | $0 | $0 | $0 | $100.6M | $100.6M | $100.6M | $100.6M | — |
| Proceeds from issuance of debt | $0 | $0 | $0 | $100.6M | $100.6M | $100.6M | $100.6M | — |
| Repurchases of common stock | $0 | $0 | $0 | $45M | — | — | — | $0 |
| Proceeds from Hedge Financing Activities | $0 | $0 | $0 | $5M | — | — | — | $0 |